RUO Aducanumab是一种选择性靶向聚集的淀粉样蛋白β的人单克隆抗体。在阿尔茨海默病转基因小鼠模型中,aducanumab显示可进入大脑,结合实质淀粉样蛋白β,并以剂量依赖性方式减少可溶性和不溶性淀粉样蛋白β。 Aducanumab生物仿制药-研究级该产品同种型对照:ICH2254 缓冲液:ICH3002 浓度:5mg/ml 纯度:>95% by SDS-PAGE 内毒素:≤ 1.0 EU/mg as determined by the LAL method 制剂:Sterile, preservative-free, solution in PBS. BSA and Azide free.